Literature DB >> 35037144

The role of T-LAK cell-originated protein kinase in targeted cancer therapy.

Lu Zhang1, Fei Wang1, Huijun Yi2, Svetlana P Ermakova3, Olesya S Malyarenko3, Jianmei Mo2, Yingze Huang2, Qiuhong Duan4, Juanjuan Xiao5, Feng Zhu6.   

Abstract

Targeted therapy has gradually become the first-line clinical tumor therapy due to its high specificity and low rate of side effects. TOPK (T-LAK cell-originated protein kinase), a MAP kinase, is highly expressed in various tumor tissues, while it is rarely expressed in normal tissues, with the exceptions of testicular germ cells and some fetal tissues. It can promote cancer cell proliferation and migration and is also related to drug resistance. Therefore, TOPK is considered a good therapeutic target. Moreover, a number of studies have shown that targeting TOPK can inhibit the proliferation of cancer cells and promote their apoptosis. Here, we discussed the biological functions of TOPK in cancer and summarized its tumor-related signaling network and known TOPK inhibitors. Finally, the role of TOPK in targeted cancer therapy was concluded, and future research directions for TOPK were assessed.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cancer resistance; Pathway; TOPK; Targeted therapy; Tumor metastasis

Mesh:

Substances:

Year:  2022        PMID: 35037144     DOI: 10.1007/s11010-021-04329-5

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  82 in total

1.  Cloning and expression of a novel MAPKK-like protein kinase, lymphokine-activated killer T-cell-originated protein kinase, specifically expressed in the testis and activated lymphoid cells.

Authors:  Y Abe; S Matsumoto; K Kito; N Ueda
Journal:  J Biol Chem       Date:  2000-07-14       Impact factor: 5.157

Review 2.  MEK1/2 dual-specificity protein kinases: structure and regulation.

Authors:  Robert Roskoski
Journal:  Biochem Biophys Res Commun       Date:  2011-12-08       Impact factor: 3.575

3.  Characterization of PDZ-binding kinase, a mitotic kinase.

Authors:  S Gaudet; D Branton; R A Lue
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

4.  Lymphokine-activated killer T-cell-originated protein kinase phosphorylation of histone H2AX prevents arsenite-induced apoptosis in RPMI7951 melanoma cells.

Authors:  Tatyana A Zykova; Feng Zhu; Chengrong Lu; LeeAnn Higgins; Yasuaki Tatsumi; Yasuhito Abe; Ann M Bode; Zigang Dong
Journal:  Clin Cancer Res       Date:  2006-12-01       Impact factor: 12.531

5.  Transformation of mammalian cells by constitutively active MAP kinase kinase.

Authors:  S J Mansour; W T Matten; A S Hermann; J M Candia; S Rong; K Fukasawa; G F Vande Woude; N G Ahn
Journal:  Science       Date:  1994-08-12       Impact factor: 47.728

6.  PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer.

Authors:  Jae-Hyun Park; Meng-Lay Lin; Toshihiko Nishidate; Yusuke Nakamura; Toyomasa Katagiri
Journal:  Cancer Res       Date:  2006-09-15       Impact factor: 12.701

7.  The ERK Cascade: Distinct Functions within Various Subcellular Organelles.

Authors:  Inbal Wortzel; Rony Seger
Journal:  Genes Cancer       Date:  2011-03

8.  Bidirectional signals transduced by TOPK-ERK interaction increase tumorigenesis of HCT116 colorectal cancer cells.

Authors:  Feng Zhu; Tatyana A Zykova; Bong Seok Kang; Zhe Wang; Mara C Ebeling; Yasuhito Abe; Wei-Ya Ma; Ann M Bode; Zigang Dong
Journal:  Gastroenterology       Date:  2007-04-25       Impact factor: 22.682

9.  Characterization of a novel mitogen-activated protein kinase kinase 1/2 inhibitor with a unique mechanism of action for cancer therapy.

Authors:  Sherif Daouti; Huisheng Wang; Wen-hui Li; Brian Higgins; Kenneth Kolinsky; Kathryn Packman; Anthony Specian; Norman Kong; Nicholas Huby; Yang Wen; Qing Xiang; Frank J Podlaski; Yang He; Nader Fotouhi; David Heimbrook; Huifeng Niu
Journal:  Cancer Res       Date:  2009-02-24       Impact factor: 12.701

10.  Activation of MEK family kinases requires phosphorylation of two conserved Ser/Thr residues.

Authors:  C F Zheng; K L Guan
Journal:  EMBO J       Date:  1994-03-01       Impact factor: 11.598

View more
  1 in total

1.  Inhibiting ALK-TOPK signaling pathway promotes cell apoptosis of ALK-positive NSCLC.

Authors:  Juanjuan Xiao; Lu Zhang; Huijun Yi; Ling Zou; Jianmei Mo; Feng Xue; Jinhua Zheng; Yingze Huang; Hui Lu; Hansheng Wu; Peipei Xue; Xin Zhang; Lifei He; Zhaoxin Li; Shigui Pang; Guibin Qiao; Qiuhong Duan; Feng Zhu
Journal:  Cell Death Dis       Date:  2022-09-27       Impact factor: 9.685

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.